Micrima Limited

About Micrima Limited

At Micrima, we're advancing women's breast health through objective breast density measurement and personalised breast cancer risk assessment. Our CE-marked Mi~Scan® technology uses radio frequency and advanced data analysis to measure breast tissue properties and provide an objective breast density assessment, with no ionising radiation, no breast compression and no referral required. Combined with Mi~Score®, women receive a personalised 5-year, 10-year and lifetime breast cancer risk assessment, helping them better understand their individual risk and have more informed conversations with healthcare professionals. We believe every woman deserves access to meaningful information about her breast health. Yet millions remain unaware of an important risk factor: breast density. Through our Know Your Normal campaign, clinical research and community partnerships, we're helping more women understand their breast density and what it could mean for their future health. Micrima's technology has been developed through more than two decades of scientific research, engineering and clinical development, including a 1,000-patient clinical trial and CE mark approval. Today, we're working with healthcare providers, employers, researchers and strategic partners to make personalised breast cancer risk assessment more accessible across the UK and internationally. Our mission is simple: To empower more women with the information they need to understand their breast density, know their breast cancer risk and take proactive control of their health.